Scorpion Venom Peptide Delivered Nasally Reduces Chronic Pain and Inflammation in Mice
A tiny peptide from scorpion venom, given through the nose, significantly reduced long-lasting pain and spinal cord inflammation in a mouse pain model.
Quick Facts
What This Study Found
Intranasal AaTs-1 significantly reduced pain hypersensitivity and neuroinflammation while preventing morpho-functional alterations in spinal cord neurons and glial cells in a formalin-induced chronic pain model.
Key Numbers
- AaTs-1 is a tetrapeptide (4 amino acids) from Androctonus australis scorpion venom
- Administered intranasally for 10 days
- Abolished mechanical allodynia and thermal hyperalgesia
- Reversed hyperactivation of spinal nociceptive-specific neurons
- Partially restored spinal cytokine balance and glial cell phenotypes
How They Did This
Animal study using formalin-induced long-lasting pain hypersensitivity in mice. AaTs-1 was administered intranasally daily for 10 days. Assessed pain responses, cytokine levels, and neuronal/glial changes in the spinal cord.
Why This Research Matters
Chronic pain remains poorly managed, and venom-derived peptides represent a novel therapeutic avenue. The intranasal delivery route is particularly promising as it bypasses the blood-brain barrier, potentially offering a non-invasive way to deliver peptide therapeutics to the central nervous system.
The Bigger Picture
Venom-derived peptides are an expanding frontier in pain research. This study adds to evidence that nature-derived peptides, combined with innovative delivery routes like intranasal administration, could offer alternatives to opioid-based pain management.
What This Study Doesn't Tell Us
Animal study only — effects in humans unknown; formalin model may not fully represent clinical chronic pain conditions; long-term safety of repeated intranasal peptide delivery not assessed; mechanism of action through FPR-2 needs further confirmation in vivo.
Questions This Raises
- ?Would AaTs-1 be effective in other chronic pain models, such as neuropathic pain?
- ?What is the optimal dose and duration for intranasal peptide delivery in larger animals or humans?
- ?Could the peptide be modified to improve its stability and potency for clinical development?
Trust & Context
- Key Stat:
- 10-day nasal treatment Daily intranasal dosing of a 4-amino-acid scorpion peptide reduced chronic pain behavior in mice
- Evidence Grade:
- Preclinical animal study providing early proof-of-concept. Promising results but far from clinical applicability without human trials.
- Study Age:
- Published in 2025, representing cutting-edge venom peptide research.
- Original Title:
- Antinociceptive and neuromodulatory effects of the scorpion venom tetrapeptide tetrascorpin-1 in a long-lasting pain hypersensitivity model in mice.
- Published In:
- Toxicon : official journal of the International Society on Toxinology, 268, 108611 (2025)
- Authors:
- Pagano, Salvatore, Limongelli, Rebecca, Moslah, Wassim, Saada, Mohamed-Chiheb, Manzo, Iolanda, Bonsale, Roozbe, Teweldemedhin, Milena Melake, Fusco, Antimo, Guida, Francesca, Belardo, Carmela, Morace, Andrea Maria, Perrone, Michela, Ricciardi, Federica, Pierretti, Gorizio, Vastarella, Maria Giovanna, Infantino, Rosmara, Srairi-Abid, Najet, Maione, Sabatino, Palazzo, Enza, Luongo, Livio
- Database ID:
- RPEP-12918
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Is it safe to use scorpion venom as medicine?
The peptide used is a tiny, purified fragment of scorpion venom — just 4 amino acids — not the whole venom. Isolated venom peptides can have therapeutic effects without the dangerous properties of whole venom, though safety testing is still ongoing.
Why deliver pain medication through the nose?
Nasal delivery can transport small peptides directly toward the brain and spinal cord, bypassing the blood-brain barrier. This means potentially faster, more targeted pain relief with lower doses than oral or injected medications.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12918APA
Pagano, Salvatore; Limongelli, Rebecca; Moslah, Wassim; Saada, Mohamed-Chiheb; Manzo, Iolanda; Bonsale, Roozbe; Teweldemedhin, Milena Melake; Fusco, Antimo; Guida, Francesca; Belardo, Carmela; Morace, Andrea Maria; Perrone, Michela; Ricciardi, Federica; Pierretti, Gorizio; Vastarella, Maria Giovanna; Infantino, Rosmara; Srairi-Abid, Najet; Maione, Sabatino; Palazzo, Enza; Luongo, Livio. (2025). Antinociceptive and neuromodulatory effects of the scorpion venom tetrapeptide tetrascorpin-1 in a long-lasting pain hypersensitivity model in mice.. Toxicon : official journal of the International Society on Toxinology, 268, 108611. https://doi.org/10.1016/j.toxicon.2025.108611
MLA
Pagano, Salvatore, et al. "Antinociceptive and neuromodulatory effects of the scorpion venom tetrapeptide tetrascorpin-1 in a long-lasting pain hypersensitivity model in mice.." Toxicon : official journal of the International Society on Toxinology, 2025. https://doi.org/10.1016/j.toxicon.2025.108611
RethinkPeptides
RethinkPeptides Research Database. "Antinociceptive and neuromodulatory effects of the scorpion ..." RPEP-12918. Retrieved from https://rethinkpeptides.com/research/pagano-2025-antinociceptive-and-neuromodulatory-effects
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.